Pharmaceutical Industry
7 articles on Pharmaceutical Industry, written by Shotlee and medically reviewed for clinical accuracy.
Pharmaceutical firms compensate Indiana physicians for discussing GLP-1 medications, data reveals
An analysis of public data shows that pharmaceutical firms paid over $533,000 to Indiana healthcare professionals in 2024 for speaking about GLP-1 medications. The funds covered travel and expenses for conferences. Experts discuss potential influences on prescribing practices, while doctors defend the educational value.
6 min read
Strategic Acquisitions and Partnerships in the GLP-1 Agonists Market: An Overview of Recent Trends
The global GLP-1 agonists market is anticipated to reach over USD 260.1 billion by 2034, demonstrating a CAGR of 19.9% during the forecast period. This growth is driven by innovations in diabetes, obesity, and cardiovascular disease treatments, though high costs and administration challenges remain.
4 min read
Mounjaro by Eli Lilly Approved for China's State Insurance Coverage for Diabetes
Mounjaro, a drug by Eli Lilly, is set to be included in China's state-run health insurance program for individuals with type 2 diabetes starting January 1. This inclusion aims to improve access to the medication, although increased sales may be balanced by reduced prices. The drug was introduced in China earlier this year.
2 min read
Ozempic's Impact: Reshaping Supermarkets and Stock Valuations
The rise in popularity of weight loss medications such as Ozempic and Mounjaro is significantly impacting both the food industry and the stock market. Eli Lilly, a pharmaceutical company, experienced a surge in valuation after reporting substantial sales increases. These drugs are changing eating patterns and redefining obesity treatment.
6 min read
Medicare Achieves 71% Discount on Novo's Ozempic and Wegovy
The U.S. government has successfully negotiated a 71% discount on Novo Nordisk's popular drugs Ozempic and Wegovy for Medicare beneficiaries. These price reductions, resulting from recent legislation, will be implemented in 2027, potentially saving millions of dollars.
5 min read
Novo Nordisk Reduces Wegovy Price Up to 37% in India Amid Mounjaro Competition
Novo Nordisk has reduced the price of Wegovy in India by as much as 37% to better compete with Eli Lilly's Mounjaro. This decision follows Mounjaro's rise to become the best-selling weight-loss medication in India by value.
2 min read
Novo Nordisk Shake-Up: What It Means for GLP-1 Innovation
Recent leadership changes at Novo Nordisk, the pharmaceutical giant behind Ozempic and Wegovy, have sparked discussions about the future of GLP-1 innovation and the company's direction. What does this mean for the future of weight loss drugs and metabolic health?
3 min read